Dupuis Jehan, Emile Jean-François, Mounier Nicolas, Gisselbrecht Christian, Martin-Garcia Nadine, Petrella Tony, Bouabdallah Reda, Berger Françoise, Delmer Alain, Coiffier Bertrand, Reyes Félix, Gaulard Philippe
Department of Hematology, Institut National de la Santé et de la Recherche Médicale (INSERM) U617 Hôpital Henri Mondor, Créteil, France.
Blood. 2006 Dec 15;108(13):4163-9. doi: 10.1182/blood-2006-04-017632. Epub 2006 Aug 10.
Peripheral T-cell lymphomas (PTCLs) are rare and have a dismal prognosis. The most frequent subtype is PTCL, unspecified. Epstein-Barr virus (EBV) has been detected in around 40% of cases, but its prognostic significance is not fully established. Lymph node samples from 110 patients with PTCL, unspecified included in LNH87 and LNH93 trials were available. EBV status was studied by EBV-encoded small RNA in situ hybridization (EBER-ISH). EBER-ISH showed positive cells in 45 (41%) of 110 patients. Pretreatment characteristics were comparable between positive and negative cases, except for male sex (80% versus 60%, respectively, P = .02). Only 50% of patients achieved complete remission with a 5-year event-free survival (EFS) and overall survival (OS) of 21% and 30%, respectively. EBER-ISH positivity was the sole factor linked with worse EFS, with a 5-year probability of 11% for positive patients. In univariate analysis, factors affecting OS were EBER-ISH positivity, high LDH level, and age older than 60 years. In multivariate analysis, EBER-ISH was associated with a worse OS in the elderly population. Time-dependent analysis showed that the negative impact of EBV was essentially seen in the first 2 years following diagnosis. These results warrant further studies regarding pathogenesis and specific treatment approaches for EBV-associated PTCL patients.
外周T细胞淋巴瘤(PTCLs)较为罕见,预后较差。最常见的亚型为未特指的PTCL。约40%的病例中检测到爱泼斯坦-巴尔病毒(EBV),但其预后意义尚未完全明确。有110例纳入LNH87和LNH93试验的未特指PTCL患者的淋巴结样本可供研究。通过EBV编码的小RNA原位杂交(EBER-ISH)研究EBV状态。EBER-ISH显示,110例患者中有45例(41%)存在阳性细胞。除男性比例外(分别为80%和60%,P = 0.02),阳性和阴性病例的预处理特征具有可比性。只有50%的患者实现完全缓解,5年无事件生存率(EFS)和总生存率(OS)分别为21%和30%。EBER-ISH阳性是与较差EFS相关的唯一因素,阳性患者的5年概率为11%。单因素分析显示,影响OS的因素为EBER-ISH阳性、高乳酸脱氢酶(LDH)水平和年龄大于60岁。多因素分析显示,EBER-ISH与老年人群较差的OS相关。时间依赖性分析显示,EBV的负面影响主要在诊断后的前2年出现。这些结果值得对EBV相关PTCL患者的发病机制和特定治疗方法进行进一步研究。